GlassScriptPhysician profile
Mohamad Erfani
NPI 1093036469
$3,035.16
in general payments reported to CMS, 2019-2025
22 companies · $72.44 in 2025
The $72.44 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $204 · 2021: $381 · 2022: $279 · 2023: $631 · 2024: $728 · 2025: $72.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,431.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $789.60 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $556.19 | 2019-2024 | Xifaxan, Trulance, Uceris |
| Gilead Sciences, INC. | $455.76 | 2019-2022 | |
| Ardelyx, INC. | $361.57 | 2022-2025 | Ibsrela |
| Boston Scientific Corporation | $221.15 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $177.96 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.59 | 2019 | |
| Madrigal Pharmaceuticals | $80.91 | 2024 | Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $58.91 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $27.63 | 2024 | Stelara |
| Glaxosmithkline, LLC. | $26.90 | 2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $20.87 | 2020 | |
| Phathom Pharmaceuticals, INC. | $20.41 | 2024 | Voquezna |
| Pfizer INC. | $19.23 | 2023 | |
| Qol Medical, LLC | $17.47 | 2024 | Sucraid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Micro-Tech Endoscopy USA, INC. | $17.41 | 2022 | |
| Intercept Pharmaceuticals, INC. | $16.73 | 2022 | |
| Shionogi INC | $16.17 | 2019 | |
| Napo Pharmaceuticals INC | $15.26 | 2019 | |
| Echosens North America, INC. | $15.00 | 2019 | |
| Braintree Laboratories, INC. | $11.84 | 2019 | |
| Nestle Healthcare Nutrition INC. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamad Erfani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.